Spectracef

Spectracef is a brand name of cefditoren, approved by the FDA in the following formulation(s):

SPECTRACEF (cefditoren pivoxil - tablet; oral)

• 
  Manufacturer: CORNERSTONE THERAP
  
  Approval date: August 29, 2001
  
  Strength(s): 200MG
  


• 
  Manufacturer: CORNERSTONE THERAP
  
  Approval date: July 21, 2008
  
  Strength(s): 400MG ^[RLD]

Has a generic version of Spectracef been approved?

No. There is currently no therapeutically equivalent version of Spectracef available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Spectracef. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Antibacterial composition for oral administration
  Patent 5,958,915
  Issued: September 28, 1999
  Inventor(s): Abe; Kenichi & Ota; Masato & Yamaguchi; Hiroyuki & Murakami; Chikako & Kikkoji; Toshihiro
  Assignee(s): Meiji Seika Kaisha, Ltd.
  A new, antibacterial composition for use in oral administration is now provided, which composition comprises a mixture of Cefditoren pivoxyl with a water soluble casein salt. This composition has a reduced bitter taste of Cefditoren pivoxyl and also has improved properties regarding the rate and concentration of dissolution of Cefditoren pivoxyl in water and a ratio of dissolution out of Cefditoren pivoxyl into water. This composition further can attain a high absorbability of the Cefditoren component at the digestive tubes upon oral administration thereof. In this composition, the ratio (by weight) of Cefditoren pivoxyl to the casein salt added may preferably be in a range of 1:0.1 to 1:4. By further addition of a water-soluble polyphosphoric acid salt to the composition, the composition can prevent a ratio of dissolution out into water of the Cefditoren pivoxyl component being decreased when the composition was stored under severe conditions.
  
  Patent expiration dates:
  
  
  • October 14, 2016
    
  
  
  
  • October 14, 2016
    
    ✓ 
    Drug product
  
  

See also...

• Spectracef Consumer Information (Wolters Kluwer)
• Spectracef Consumer Information (Cerner Multum)
• Spectracef Advanced Consumer Information (Micromedex)
• Spectracef AHFS DI Monographs (ASHP)
• Cefditoren Pivoxil Consumer Information (Wolters Kluwer)
• Cefditoren Consumer Information (Cerner Multum)
• Cefditoren pivoxil Advanced Consumer Information (Micromedex)
• Cefditoren Pivoxil AHFS DI Monographs (ASHP)